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testing also provides preliminary quantitative item performance data and important 
insights about the usability of eDiaries.
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Objectives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) which 
is a classification and diagnostic system for psychiatric and certain neurologic con-
ditions. DSM-5 brings significant changes to many of the diagnostic categories as 
compared to the previous edition of the manual. The objective of this review was 
to examine the changes in the Autism Spectrum Disorder (ASD) criteria and dis-
cuss the impact of these changes for industry. MethOds: A line-by-line review 
of the DSM-5 criteria for Autism Spectrum Disorder and the DSM-IV criteria for 
Pervasive Developmental Disorders was undertaken. Significant changes were 
highlighted and discussed from the point of view of sponsors of clinical trials for 
psychopharmacologic agents being developed to treat these conditions. Results: 
The changes to the diagnostic criteria for what were known in DSM-IV as pervasive 
developmental disorders (PDD) are sweeping. ASD, now in a section of the DSM 
titled “Neurodevelopmental Disorders,” is a single entity in DSM-5 with several 
levels of severity that effectively replaces the five PDDs that were separately clas-
sified in DSM-IV. Notable changes include the addition of severity levels to the ASD 
criteria, changes to the social interaction and social communication criteria, and 
the addition of hyper- or hyporeactivity to sensory input or unusual interest in sen-
sory aspects of the environment, as an illustrative example of restrictive, repetitive 
patterns of behavior, interests, or activities. cOnclusiOns: The numerous and 
significant changes in DSM-5 pose both challenges and opportunities to industry. We 
need to take a careful look at DSM-5 to understand what the changes mean for how 
we go about developing medical products to treat psychiatric disorders. This means 
the need for investment in research, education, and new ways of approaching the 
development of endpoints and outcome assessments in clinical trials.
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Objectives: The impact of addictive substance abuse (SA) on overall well-being, 
such as patient’s self-reported health status, may suffer from endogeneity bias. The 
purpose of this study is to estimate the impact of SA on patient’s health status using 
the instrumental variable (IV) approach. MethOds: The sample was extracted from 
the 2011 Substance Abuse and Mental Health Services Administration (SAMHSA) 
data for 36,347 adult US respondents who indicated SA status. Treating SA as exog-
enous, a single-equation probit model was used. Treating SA as endogenous, bivari-
ate probit models were employed using different IVs. The outcome variable was the 
self-reported health status (1= better than good; 0= fair or poor). Other exogenous 
variables controlled in the model were respondents’ age, gender, race, marital status, 
education level, employment status and family income. IVs were respondents’ age 
at SA initiation, SA frequency and substance availability. Exogeneity, over-iden-
tification and weak instrument tests were performed to ensure the validity and 
appropriateness of the IVs. Results: About 50% of the respondents were between 
18-25 years old. Over 56% indicated SA and approximately 36% had initiated SA 
before age 18. The single-equation probit suggested that SA was associated with 
at least a 2% decrease in overall health status (p< 0.01), compared those who never 
had SA. After adjusting for endogeneity bias, the negative relation between SA and 
health status increased by at least two-fold (p< 0.01). All tests indicated that the 
IVs used were valid and the results were significant. cOnclusiOns: The findings 
suggest that estimating the impact of SA on health status should consider adjust-
ing the endogeneity bias induced by individual characteristics and environmental 
factors such as age at SA initiation, frequency of SA use and substance availability 
in the community. Further investigations on the effect of SA abstinence durations 
on health status should be explored to strengthen their associations.
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Objectives: In May 2013, the American Psychiatric Association released the 
fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) 
which is a classification system for psychiatric and certain neurologic conditions. 
DSM-5 brings significant changes to many diagnostic categories as compared to 
the previous edition of the manual. The objective of this review was to examine the 
changes in the Attention-Deficit/Hyperactivity Disorder (ADHD) criteria and discuss 
the impact these changes may have for industry. MethOds: A line-by-line review 
of the DSM-5 and DSM-IV criteria for ADHD was undertaken. Significant changes 
were highlighted and discussed from the point of view of sponsors of clinical trials 
for psychopharmacologic agents being developed to treat ADHD. Results: One of 
the more notable changes to ADHD criteria in DSM-5 is in the age of onset cutoff. 
To meet DSM-IV criteria, symptoms had to be present before age 7. In DSM-5 this 
was changed to 12. Additionally, symptoms present before the age of onset cutoff 
had to cause impairment to meet the DSM-IV criteria, but in DSM-5 there is no 
such requirement. Another significant change lies in the fact that while DSM-IV 
did not make a distinction between childhood and adult ADHD, in DSM-5, from 
age 17 on, only 5 of 9 symptoms in one or both categories are required, rather than 
6. Several other changes related to differential diagnosis and functional impair-
ment were noted as well. cOnclusiOns: The significant changes in DSM-5 pose 
Objectives: In the last years, the assessment of patient satisfaction has become 
an area of great interest due to its implications, especially in the management of 
chronic diseases. Across the board, satisfied patients tend to have better adher-
ence to medication. It affects a patient’s prognosis and treatment costs. High-risk 
hypertension and Diabetes Mellitus (DM) (types I and II) are two chronic diseases 
with high prevalence. The objective of this research was to examine Differential 
Item Functioning in a previously developed Satisfaction with Treatment item bank 
between these chronic diseases as a first step to improve the item bank. MethOds: 
The sample consisted of a total of 283 patients diagnosed with DM and 1.517 high or 
very high-risk hypertensive patients. Uniform DIF between both samples was inves-
tigated using Winsteps. The presence of DIF in thirteen items from a satisfaction 
bank was analyzed. Results: Ceiling effect was detected and an item-person map 
showed that the test was off-target and didn’t cover the highest range of the ability 
scale. DIF was present between patients with Diabetes Mellitus (I and II) and high-
risk hypertensive patients. Differences above one logit were found in three items, 
two related to adverse-events, which diabetes patients found harder to endorse, and 
one to oversights, harder to endorse for high-risk hypertensive patients. A differ-
ence in the same direction was found in two more items pertaining to convenience, 
with differences in this case larger than 0.75 logits. cOnclusiOns: This study 
represents a psychometrically valid initial effort to improve patients with chronic 
diseases satisfaction assessment. The DIF analysis has allowed improving the item 
satisfaction bank, selecting those items which could provide better information in 
order to develop a satisfaction questionnaire better tailored to specific patients. 
Future research is recommended considering different chronic pathologies and to 
reduce the ceiling effect associated with the satisfaction measures.
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Objectives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a 
classification system for psychiatric and certain neurologic conditions. DSM-5 
brings significant changes to many diagnostic categories as compared to the 
previous DSM-IV-TR. The objective of this review was to examine the changes 
in the Schizophrenia criteria and discuss the impact these changes may have 
for industry. MethOds: A line-by-line review of the DSM-5 and DSM-IV criteria 
was undertaken. Significant changes were highlighted and discussed from the 
point of view of sponsors of clinical trials for psychopharmacologic agents being 
developed to treat Schizophrenia. Results: The primary diagnostic criteria for 
Schizophrenia in DSM-5 are little changed. The major change in the so-called 
“active-phase symptoms” is with the mix of symptoms that can meet this crite-
rion. Five key symptom areas must be present to meet criteria. In DSM-IV, any two 
symptoms were sufficient and in some limited cases, even just one was enough 
(bizarre delusions or Schneiderian first-rank auditory hallucinations – convers-
ing voices). According to the DSM-5 criteria, there always must be at least two 
symptoms to meet Criterion A, and one of the two must be either delusions, hal-
lucinations, or disorganized speech. Other important changes include changes to 
the course specifiers, the elimination of Schizophrenia subtypes, and the addition 
of an optional framework for clinicians to rate the severity of the primary symp-
toms. cOnclusiOns: The changes in DSM-5 pose both challenges and opportu-
nities for industry. The changes in the DSM-5 criteria may translate into changes 
for how we go about developing medical products to treat psychiatric disorders, 
including Schizophrenia. There will need to be an investment in research and edu-
cation, and sponsors must examine the possibility of developing new endpoints 
and outcome assessments for use in clinical trials.
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Objectives: To pilot test daily electronic symptom diaries in pediatric chronic 
constipation (CC) and irritable bowel syndrome with constipation (IBS-C) for approx-
imately one week prior to cognitive debriefing interviews. MethOds: Separate 
child and parent eDiary measures of CC/IBS-C symptoms were developed based 
on concept elicitation interviews with children with CC/IBS-C and their parents. 
The eDiaries were completed by 36 children/adolescents (aged 6-17 years) with 
CC/IBS-C and 30 parents (of 6 month-11 year old children with CC/IBS-C) for 5-9 
days prior to cognitive debriefing. Children and parents were trained to use the 
eDiary and following the pilot test, children and parents were interviewed sepa-
rately about their experiences completing the eDiaries and the symptom items. 
Item descriptive statistics were calculated using the eDiary data collected during the 
pilot test. Results: Both eDiaries were well understood, all items were considered 
relevant, and no symptoms were identified as missing from the eDiaries. During 
cognitive debriefing, the children were able to reflect on their experiences of com-
pleting the eDiary as opposed to considering hypothetical scenarios to debrief the 
items. Although 9 children and 15 parents reported challenges with transmitting 
data, mean compliance rates were high (94% and 92%, respectively), indicating low 
levels of missing data and that the eDiaries were easy to use overall. Mean comple-
tion times were 3.72 minutes for children and 3.96 minutes for parents, provid-
ing further evidence of low burden. All item responses were normally distributed 
and demonstrated expected patterns of response (e.g., most reported 0 or 1 bowel 
movement daily). cOnclusiOns: Pilot testing eDiaries prior to cognitive debrief-
ing interviews, especially with children, provides respondents with the experience 
of completing the eDiary, facilitating a more informed qualitative interview. Pilot 
